ARC-21 (Gastrointestinal Cancer)
What is the Purpose of this Study?
If you choose to join this study, you will:
- Receive the study drugs, domvanalimab and zimberelimab, through an IV once every 3 or 4 weeks
- Receive standard chemotherapy every 2 weeks in addition to the study drugs (if not previously treated)
- Have blood draws
- Get CT or MRI scans every 6-to-12 weeks
- Receive the study drugs, domvanalimab and zimberelimab, through an IV once every 3 or 4 weeks
- Receive standard chemotherapy every 2 weeks in addition to the study drugs (if not previously treated)
- Have blood draws
- Get CT or MRI scans every 6-to-12 weeks
What is the Condition Being Studied?
Gastroesophageal Adenocarcinoma
Who Can Participate in this Study?
Adults ages 18+ who are diagnosed with one of the following types of cancer:
- Esophageal adenocarcinoma (a common type of cancer of the esophagus); OR
- Gastroesophageal junction adenocarcinoma (cancer where the esophagus meets the stomach); OR
- Gastric adenocarcinoma (stomach cancer)
The cancer must not be treatable with surgery alone.
For more information about who can join this study, please contact the study team at 919-668-1861.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.
Study Details
Full Title
A Phase 2 Trial to Evaluate the Safety and Efficacy of Domvanalimab (AB154) and Zimberelimab (AB122) -Based Treatment Combinations in Patients with Advanced Upper Gastrointestinal Tract Malignancies
Principal Investigator
Contacts
Gastrointestinal Oncology DCI Clinical Research Team
Email: gi-oncology-cru@dm.duke.edu
Phone: +1 919-668-1861
Protocol Number
IRB:
PRO00111012
NCT:
NCT05329766
ClinicalTrials.gov
View on ClinicalTrials.gov